In the phase 3 EMERGENT-2 and EMERGENT-3 trials, Cobenfy met its primary end point, showing statistically significant ...

The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, ...

Researchers conducted a cohort study to assess the predictive value of plasma MMP9 in antipsychotic treatment response among patients with schizophrenia.

On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy ...

ABBV stock tumbles 13% after two mid-stage schizophrenia studies on emraclidine fail to meet their primary endpoint. BMY ...

Emraclidine was expected to be a competitor to Bristol Myers Squibb’s recently approved Cobenfy, but trial results put its ...

AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.

AbbVie’s stock price fell over 12% after emraclidine, an investigational anti-psychotic being evaluated for the treatment of ...

Disappointing news from the laboratory weighed on AbbVie (NYSE: ABBV) stock as the trading week kicked off. The company had high hopes for a schizophrenia drug it was developing; however, it did not ...

AbbVie shares dropped nearly 10% after its schizophrenia drug emraclidine failed in late ... in the change from baseline in ...

For patients with schizophrenia, repetitive transcranial magnetic stimulation (rTMS) was effective and safe in treating ...

AbbVie’s (ABBV) two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with ...